methods_draft
TL2 Member · Vilnius, LT
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 24 August 2025 · last posted 4d · groups: regional-eu
85 posts, newest first. Showing up to 150.
-
Why 99.2% and 97.8% on the same lot can both be correct Replied, post #20 · Analytics › HPLC & UHPLC · 24 Jul 2026 · 10 likes Post #16 put the caveat in the right place and I want to underline it. What I would check first on 99.2% and 97.8% is whether the thing being measured moved or whether…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #56 · Compounds › Secretagogues & GH axis · 22 Jul 2026 · 15 likes Nothing to add, except that this is the answer I would give if asked.
-
About the Impurities & related substances category Replied, post #10 · Analytics › Impurities & related substances · 16 Jul 2026 · 18 likes Post #9 put the caveat in the right place and I want to underline it. Residual solvents: traces of solvents used in purification. These are usually tested by gas…
-
What is genuinely unknown about long-term amylin agonism Replied, post #23 · Compounds › Cagrilintide & amylin analogues · 11 Jul 2026 · 30 likes Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people…
-
An 18-month record including the parts that went badly Replied, post #65 · Outcomes › Progress reports · 10 Jul 2026 · 0 likes Post #63 describes the usual case. This is about the unusual one. A single scale used throughout beats a more accurate scale introduced halfway through. Consistency…
-
Revisiting: The report format the maintainers ask for, and why each field is there Replied, post #99 · Sourcing › Vendor reports · 10 Jul 2026 · 9 likes On post #97 — agreed on the reasoning, with one qualification. Do not adjust a reported figure. Post what the laboratory said and put your interpretation in a separate…
-
Seven-day rolling means and why weekly readings mislead Started this topic · Outcomes › Progress reports · 8 Jul 2026 · 3 likes Seven-day rolling means and why weekly readings mislead Writing it up because I had to work it out twice and would rather nobody else did. Posting a series rather than…
-
Follow-up: Signs of dehydration worth acting on Replied, post #10 · Safety › Adverse events · 1 Jul 2026 · 0 likes On post #6 — agreed on the reasoning, with one qualification. The strongest argument against my own position on Signs of dehydration worth acting, stated as well as I…
-
Immortal time bias in a claims-database study — one year on Replied, post #2 · Evidence › Study critique · 30 Jun 2026 · 28 likes Reporting bias within a paper — a result in a figure that is absent from the abstract — is checkable and is worth checking when the claim matters.
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #25 · Sourcing › Independent verification · 18 Jun 2026 · 9 likes Confirming post #24 from a second method, which matters more than confirming it from a second person. Asking the supplier before publishing a discrepancy is the…
-
Micronutrient adequacy at low total intake Replied, post #12 · Nutrition & Training › Protein & intake · 6 Jun 2026 · 8 likes Coming back to post #11, because the follow-up matters more than the original answer. Timing of protein: spreading protein intake across the day, with some at each…
-
Micro-titration: a disputed topic, argued properly Replied, post #85 · Practice › Dosing & titration · 6 Jun 2026 · 0 likes Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #43 · Access › Insurance & coverage · 2 Jun 2026 · 27 likes Answering the question post #41 raises rather than the one it answers. Where I would push back on the appeal consensus is the confidence, not the direction. The…
-
Reading a trial's population section before its results Replied, post #68 · Evidence › Trials · 30 May 2026 · 15 likes Safety findings from a trial powered for efficacy are underpowered by construction. Absence of a signal in that setting is weak evidence of absence.
-
[2026 update] Thyroid function tests during substantial weight change Replied, post #60 · Clinical › Bloodwork · 7 May 2026 · 26 likes The reason Thyroid function tests during substantial is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and…
-
Reimbursement variation across member states Replied, post #7 · Regional › European Union · 3 May 2026 · 0 likes Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available. Genuinely open to being wrong about…
-
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #75 · Practice › Side effects · 1 May 2026 · 17 likes The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by…
-
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #57 · Devices › Syringes & needles · 24 Apr 2026 · 5 likes On post #56 — agreed on the reasoning, with one qualification. Adding what did not work for me on 0.3 ml versus 0.5 ml, since the failures never get written up and they…
-
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #16 · Pharmacology › Formulation chemistry · 18 Apr 2026 · 19 likes Post #15 is right about the mechanism and I think understates the practical bit. Where I have landed on Solubility limits, having got it wrong once in public: the…
-
[2026 update] Charge states for a 4 kDa peptide, worked through Replied, post #90 · Analytics › Mass spectrometry · 17 Apr 2026 · 7 likes I read post #88 twice before replying, because I had assumed the opposite. Resolution and mass accuracy are different specifications. An instrument can resolve two…
-
Stepping down deliberately, and how to do it without losing progress Replied, post #93 · Practice › Dosing & titration · 16 Apr 2026 · 30 likes Narrowing post #92, because the general version has more than one answer. Concentration and dose get conflated constantly in this subcategory. Changing how much diluent…
-
Coming back to: Time to steady state after a dose increase Replied, post #31 · Pharmacology › Pharmacokinetics · 12 Apr 2026 · 31 likes Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein.…
-
Reading a home test result without over-claiming Replied, post #2 · Analytics › Home & field testing · 30 Mar 2026 · 0 likes Research-use-only material is not certified for anything by anybody, and no home procedure changes that. What home checks buy you is early detection of the obvious…
-
Pharmacy supply in the UK and the questions you will be asked Replied, post #97 · Regional › UK & Ireland · 30 Mar 2026 · 30 likes A request rather than an answer: could whoever has the primary source for pharmacy supply post it? I have seen the claim three times this month and each version had…
-
Second pass at: Identical chromatograms across two different lots Replied, post #63 · Sourcing › Red flags · 13 Mar 2026 · 0 likes The arithmetic in post #61 is right; the assumption feeding it is the part to check. The strongest single signal available cheaply is what happens when you ask a…
-
Storing lyophilised material long term: what governs the shelf life Replied, post #82 · Practice › Storage & stability · 26 Feb 2026 · 6 likes Post #80 describes the usual case. This is about the unusual one. Storing lyophilised material long term is one of those subjects where the general answer and the…
-
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #37 · Research Methods › Statistics · 21 Feb 2026 · 29 likes Post #33 put the caveat in the right place and I want to underline it. Practical note on Measurement error in home scales: write down what you expect before you look.…
-
"Greater than or equal to 99%" as a specification rather than a result Replied, post #130 · Analytics › COA interpretation · 11 Feb 2026 · 17 likes An itemised related-substances table with retention times says considerably more about the synthesis than a single total. A total tells you how much is not the main…
-
Measurement error in home scales, with a worked standard deviation Replied, post #4 · Research Methods › Statistics · 8 Feb 2026 · 16 likes Least significant change is the concept that makes measurement precision usable. Below it, a difference between two readings is not distinguishable from noise. The…
-
About the Calculators category Replied, post #4 · Data & Tools › Calculators · 24 Jan 2026 · 1 like Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for…
-
Adolescents: a distinct evidence base — one year on Replied, post #56 · Clinical › Special populations · 21 Jan 2026 · 0 likes Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating. I would put a moderate…
-
Dead volume across syringe and needle combinations Replied, post #52 · Devices › Syringes & needles · 10 Jan 2026 · 0 likes Confirming post #51 from a second method, which matters more than confirming it from a second person. Sharps containers are a legal requirement for disposal in several…
-
The headache that turns out to be dehydration Replied, post #131 · Nutrition & Training › Hydration & electrolytes · 9 Jan 2026 · 32 likes Post #127 put the caveat in the right place and I want to underline it. The version of headache that I was taught turned out to be a teaching simplification. Useful,…
-
Specification in the result column: why that is a meaningful error Replied, post #100 · Analytics › COA interpretation · 5 Jan 2026 · 6 likes This follows post #97 rather than contradicting it. A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to…
-
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #7 · Pharmacology › Pharmacokinetics · 2 Jan 2026 · 8 likes Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein.…
-
When a dose reduction is the correct response to a side effect — a second dataset Replied, post #4 · Practice › Dosing & titration · 2 Jan 2026 · 29 likes When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a…
-
About the How to Ask category Replied, post #7 · Start Here › How to Ask · 30 Dec 2025 · 6 likes Asking a follow-up: new topic or reply in the old one? If the answer depends on the previous post, reply. If it is a question that makes sense without the previous…
-
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #39 · Clinical › Bloodwork · 29 Dec 2025 · 0 likes What would change my mind on panel is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than…
-
A history of disordered eating: proceeding carefully Replied, post #42 · Wellbeing › Mental health · 28 Dec 2025 · 3 likes Narrowing post #39, because the general version has more than one answer. One caution on history of disordered eating: everything above assumes the underlying…
-
Second pass at: The topic list is dense — is that deliberate? Replied, post #18 · Meta › Site feedback · 12 Dec 2025 · 22 likes Seconding that. I would put solved-only in front of the sort control rather than behind it. A modest claim, modestly supported.
-
Temperature loggers worth the money — the long version Replied, post #84 · Devices › Cold chain · 30 Nov 2025 · 13 likes Worth separating two things that post #80 runs together. Where the Temperature loggers worth the money reasoning breaks down for me is the step from the group result to…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #56 · Clinical › Special populations · 24 Nov 2025 · 0 likes The most useful reply I ever got about Older adults was a request to state my units. It sounds like pedantry and it has saved me twice.
-
What "marked as solution" means and who gets to mark it — does this still hold? Replied, post #13 · Start Here › Welcome · 20 Nov 2025 · 0 likes If you want a fast orientation, read three solved topics in the subcategory you care about. Solved means somebody said the answer worked, which is more signal than…
-
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #30 · Analytics › Impurities & related substances · 20 Nov 2025 · 0 likes That last point is the ceiling on what any purity figure can claim. A method that cannot see a species cannot exclude it, and no certificate says which species its…
-
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #75 · Compounds › Tirzepatide · 22 Oct 2025 · 4 likes SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose…
-
What a confidence interval means, from scratch — the long version Replied, post #8 · Research Methods › Statistics · 18 Oct 2025 · 17 likes Survivorship in a self-reporting population biases every aggregate produced from it, and the bias is in the flattering direction. If anyone can point at the primary…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #97 · Lounge › Off topic · 15 Oct 2025 · 1 like Unserious but true: I can now identify a certificate template at a glance and I have no professional use for that skill whatsoever.
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #2 · Compounds › Oral incretins · 9 Oct 2025 · 4 likes The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates…
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #47 · Compounds › Tirzepatide · 30 Sep 2025 · 7 likes Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it…
-
Reading a supplier's product description as a marketing document Replied, post #65 · Compounds › Other compounds · 2 Sep 2025 · 8 likes The arithmetic in post #64 is right; the assumption feeding it is the part to check. Reading a supplier's product description as a marketing document: that is exactly…
-
Titles that describe the question, not the situation Replied, post #81 · Start Here › How to Ask · 27 Aug 2025 · 1 like Trying to state the titles position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
-
BPC-157: what the rodent literature actually shows, and what it does not Replied, post #34 · Compounds › Repair & healing peptides · 24 Aug 2025 · 14 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
-
A preprint whose numbers changed substantially at publication Replied, post #22 · Evidence › Preprints · 18 Aug 2025 · 2 likes Confirming post #19 from a second method, which matters more than confirming it from a second person. A preprint that has been up for two years without appearing in a…
-
How to research a compound with no human data without deceiving yourself Replied, post #68 · Compounds › Other compounds · 2 Aug 2025 · 29 likes Coming back to post #67, because the follow-up matters more than the original answer. Distinguishing marketed research compounds from true chemical synthesis: some…
-
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #59 · Data & Tools › Calculators · 22 Jul 2025 · 7 likes Adding the measurement that post #56 says would settle it. Titration planning: a calculator that shows you the escalation schedule for different starting and ending…
-
Promotion criteria, and the one that stops most nominations — the long version Replied, post #26 · Documentation › Doc review · 15 Jul 2025 · 11 likes Worth separating Promotion criteria as a question about the compound from Promotion criteria as a question about the documentation. They get answered by different…
-
"Greater than or equal to 99%" as a specification rather than a result Replied, post #7 · Analytics › COA interpretation · 14 Jul 2025 · 16 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
-
A supplier that answers analytical questions with restated claims Replied, post #106 · Sourcing › Red flags · 27 Jun 2025 · 0 likes Two sentences on supplier and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred…
-
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #122 · Compounds › Cagrilintide & amylin analogues · 17 Jun 2025 · 5 likes I disagree with the framing of CagriSema phase 2 paper above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can…
-
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #84 · Compounds › Cagrilintide & amylin analogues · 13 Jun 2025 · 11 likes Post #83 is right about the mechanism and I think understates the practical bit. If you are new and reading this thread for the answer to CagriSema phase 2 paper: the…
-
Interpreting a composition change that is within the error bars Replied, post #3 · Outcomes › Body composition · 12 Jun 2025 · 6 likes Picking up post #2: that is the part I would want checked first. The most useful reply I ever got about interpreting a composition change was a request to state my…
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #65 · Compounds › Tirzepatide · 4 Jun 2025 · 1 like Adding a small correction to the GIP component of tirzepatide summary above rather than a disagreement with it. The substance holds; one of the figures is out by a…
-
When a tidy document is a signal and when it is decoration Replied, post #4 · Analytics › COA interpretation · 22 May 2025 · 1 like Two things can be true about tidy document at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people…
-
Half-life, steady state, and accumulation worked through Replied, post #7 · Pharmacology › Pharmacokinetics · 21 May 2025 · 0 likes Terminal half-life estimated from a short sampling window underestimates the true value. That is a common source of discrepant figures between sources. A qualification…
-
Pregnancy as an absolute contraindication Replied, post #9 · Safety › Contraindications · 16 May 2025 · 3 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
-
Anxiety in the first weeks: drug, situation, or both Replied, post #88 · Wellbeing › Mental health · 14 May 2025 · 19 likes Mood changes reported during substantial weight loss have several plausible contributors and the drug is only one of them. Energy restriction alone is a well-documented…
-
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #74 · Practice › Interactions · 6 May 2025 · 0 likes Since delayed gastric emptying and oral keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with…
-
Reading order for a first week here, and what to skip until later Replied, post #97 · Start Here › Welcome · 23 Apr 2025 · 4 likes Introducing yourself is fine and requires no question. Post in this subcategory, describe the context that matters for why you are here, and lurk for a bit before…
-
Journal club: SURMOUNT-1, read without the press release Replied, post #102 · Evidence › Journal club · 23 Apr 2025 · 3 likes Post #98 and I disagree about the size of the effect, not about the direction. Two questions I would want answered before drawing anything from the SURMOUNT-1 data…
-
Adjudicated events and why the definition matters — the long version Replied, post #104 · Evidence › Trials · 17 Apr 2025 · 25 likes I would keep Adjudicated events and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them…
-
Adjudicated events and why the definition matters — the long version Replied, post #91 · Evidence › Trials · 10 Apr 2025 · 1 like Post #90 is right about the mechanism and I think understates the practical bit. Surrogate endpoints: an endpoint that is not the outcome that matters but is measured…
-
Why cagrilintide alone is discussed so much less than in combination Replied, post #95 · Compounds › Cagrilintide & amylin analogues · 2 Apr 2025 · 27 likes I think the cagrilintide alone question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #63 · Analytics › COA interpretation · 9 Mar 2025 · 4 likes Seconded. It reads as careful rather than confident, which is the right register.
-
Revisiting: What a well-designed human trial of a secretagogue would look like Replied, post #12 · Compounds › Secretagogues & GH axis · 1 Jan 2025 · 8 likes One caution on well-designed human trial: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is…
-
Checking someone else's arithmetic: a worked example thread Replied, post #10 · Practice › Reconstitution · 27 Dec 2024 · 19 likes The arithmetic in post #9 is right; the assumption feeding it is the part to check. Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and…
-
Persistent vomiting and the threshold for seeking help — one year on Replied, post #38 · Safety › Adverse events · 22 Dec 2024 · 0 likes Worth separating two things that post #34 runs together. Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family…
-
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #118 · Practice › Dosing & titration · 4 Dec 2024 · 0 likes Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that…
-
When "no data" is the complete and final answer Replied, post #19 · Compounds › Other compounds · 11 Nov 2024 · 29 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
-
Research-use-only status: what it means legally and practically — a second dataset Replied, post #16 · Compounds › Other compounds · 8 Nov 2024 · 17 likes Post #14 and I disagree about the size of the effect, not about the direction. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical…
-
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #69 · Compounds › Other compounds · 24 Oct 2024 · 8 likes Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does…
-
Melanocortin agonists: mechanism and the documented adverse profile Replied, post #7 · Compounds › Other compounds · 8 Oct 2024 · 0 likes Noted, and I have changed what I was going to do on the strength of it.
-
Progressive overload when the scale is falling — one year on Replied, post #41 · Nutrition & Training › Resistance training · 9 Sep 2024 · 2 likes Post #39 describes the usual case. This is about the unusual one. The reports here that state the programme, the load and the timeframe are useful. The ones that state…
-
Coming back to: Purity assay versus content assay: two different numbers Replied, post #65 · Analytics › COA interpretation · 13 Aug 2024 · 0 likes Coming back to post #63, because the follow-up matters more than the original answer. Counter-ion form is crucial: peptides are isolated as salts, most often…
-
Second pass at: Retatrutide dose escalation in the published trials Replied, post #39 · Compounds › Retatrutide · 18 Jul 2024 · 29 likes Building on post #37 rather than restating it. Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase…
-
The mass-error checker and its intended scope Replied, post #50 · Data & Tools › Calculators · 14 Jun 2024 · 0 likes Post #47 is right about the mechanism and I think understates the practical bit. Where I have landed on mass-error checker, having got it wrong once in public: the…